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RESUmEn 
Objetivo: Evaluar la adhesión al tratamien-
to medicamentoso por medio de la Prueba 
de Morisky-Green e identificar las variables 
relacionadas. Método: Estudio longitudinal 
y retrospectivo. Fueron estudiados a 283 hi-
pertensos (62,5% mujeres, 73,4 (10,9) años), 
quienes fueron seguidos por un programa de 
gestión de enfermedades crónicas durante 
17 meses, los años 2011 y 2012. Todas las 
acciones del programa las llevaron a cabo 
enfermeras y consistieron en orientaciones 
por contactos telefónicos y visitas domicilia-
rias, con periodicidad según la estratificación 
de riesgo de los clientes. Resultados: Se veri-
ficó un incremento significativo (p<0,05) en 
la adhesión al tratamiento (25,1% vs 85,5%) 
y disminución en la presión arterial. Fueron 
más adherentes al tratamiento (p<0,05) los 
hipertensos con insuficiencia renal crónica y 
aquellos bajo el tratamiento con Inhibidores 
de la Enzima Convertidora de Angiotensina. 
Los hipertensos que usaban Bloqueadores 
de los Receptores de Angiotensina fueron 
menos adherentes (p<0,05). Conclusión: Se 
considera que estrategias como la gestión 
de enfermedades crónicas, realizada por en-
fermeros, puedan aumentar la adhesión de 
hipertensos al tratamiento y, de esa manera, 
contribuir para el control de los niveles ten-
sionales, minimizando el perfil de morbimor-
talidad de dichas personas. 
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RESUmo 
Objetivo: Avaliar a adesão ao tratamen-
to medicamentoso por meio do Teste de 
Morisky-Green e identificar as variáveis re-
lacionadas. Método: Estudo longitudinal e 
retrospectivo. Foram estudados 283 hiper-
tensos (62,5% mulheres, 73,4 (10,9) anos), 
os quais foram seguidos por um programa 
de gestão de doenças crônicas durante 17 
meses, nos anos 2011 e 2012. Todas as 
ações do programa foram realizadas por en-
fermeiras e consistiram em orientações por 
contatos telefônicos e visitas domiciliares, 
com periocidade de acordo com a estrati-
ficação de risco dos clientes. Resultados: 
Verificou-se aumento significativo (p<0,05) 
na adesão ao tratamento (25,1% vs 85,5%) 
e diminuição na pressão arterial. Foram 
mais aderentes ao tratamento (p<0,05) os 
hipertensos com insuficiência renal crônica 
e aqueles sob o tratamento com Inibidores 
da Enzima Conversora de Angiotensina. Os 
hipertensos que usavam Bloqueadores dos 
Receptores de Angiotensina foram menos 
aderentes (p<0,05). Conclusão: Considera-
se que estratégias como o gerenciamento 
de doenças crônicas, realizado por enfer-
meiros, possam aumentar a adesão de hi-
pertensos ao tratamento e dessa forma con-
tribuir para o controle dos níveis tensionais, 
minimizando o perfil de morbimortalidade 
dessas pessoas.
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AbStRAct 
Objective: This study assessed pharma-
cological treatment adherence using the 
Morisky-Green Test and identified related 
variables. Method: A longitudinal and re-
trospective study examined 283 patients 
with hypertension (62.5% women, 73.4 
[10.9] years old) who were being moni-
tored by a chronic disease management 
program for 17 months between 2011 and 
2012. Nurses performed all the actions of 
the program, which consisted of advice via 
telephone and periodic home visits based 
on the risk stratification of the patients. 
Results: A significant increase in treat-
ment adherence (25.1% vs. 85.5%) and a 
decrease in blood pressure were obser-
ved (p<0.05). Patients with hypertension 
and chronic renal failure as well as those 
treated using angiotensin-converting en-
zyme inhibitors were the most adherent 
(p<0.05). Patients with hypertension who 
received angiotensin receptor blockers 
were less adherent (p<0.05). Conclusions: 
Strategies such as nurse-performed chro-
nic disease management can increase 
adherence to anti-hypertensive treatment 
and therefore contribute to the control of 
blood pressure, minimizing the morbidity 
profiles of patients with hypertension. 
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intRodUction
Over the last decade, cardiovascular diseases, es-
pecially ischemic heart disease (myocardial infarction), 
stroke, hypertension, and congestive heart failure have 
become the major causes of mortality worldwide, ac-
counting for approximately 30% of all deaths and compris-
ing up to 50% of the mortality cases classified as chronic 
non-communicable diseases. These diseases cause 17 mil-
lion deaths worldwide each year(1). 
Hypertension is recognized as a major current public 
health problem(2). A quantitative systematic review com-
posed of 44 studies across 35 countries published be-
tween 2003 and 2008 revealed overall hypertension rates 
of 37.8% and 32.1% in men and women, respectively(3). 
No study has characterized the prevalence of this disease 
in Brazil. Population-based studies conducted over the last 
decade in various Brazilian cities have indicated differences 
in the prevalence of hypertension such as in Luzerna (Santa 
Catarina)(4) with 14.7%; Sinop (Mato Grosso)(5) with 23.2%; 
Salvador (Bahia)(6) with 29.9%; São Paulo (São Paulo)(7) with 
32%; Goiânia (Goiás)(8) with 36.4%; and Campo Grande 
(Mato Grosso do Sul)(9) with 41.4%. A meta-analysis and 
systematic literature review estimated a 68% prevalence of 
hypertension among the elderly in Brazil(10). 
In addition to the high prevalence of hypertension, the 
unsatisfactory control of hypertension is an issue that is 
directly related (in most cases) to treatment adherence. 
Treatment adherence can be considered the degree of 
compliance with the therapeutic measures indicated, 
whether medicinal or not, with the aim of keeping blood 
pressure at normal levels(11). 
The levels of adherence to the treatment of hyper-
tension oscillate at approximately 30%(12). The major fac-
tors that likely affect patient adherence to treatment are 
related to 1) patient characteristics such as age, gender, 
marital status, religion, lifestyle, cultural aspects, and 
health beliefs; 2) disease characteristics such as chronic-
ity and deleterious long-term effects; 3) pharmacologi-
cal treatment aspects such as the undesirable effects of 
medications and complex dosages; 4) institutional as-
pects; and 5) the relationship between the patient and 
the healthcare team members. With regard to the latter, 
the inclusion of healthcare team members such as the 
nurse tends to favor treatment adherence(13). Important-
ly, telephone contact also positively affects chronic dis-
ease treatment adherence(14). 
To be able to achieve and maintain controlled blood 
pressure levels, patients with hypertension often require 
constant encouragement with regard to lifestyle changes 
and treatment adjustments. Therefore, it is important to 
direct programs and health policies to treat hypertension. 
Chronic disease management models are one of the 
proposed solutions to increase treatment adherence. This 
new model of care began in American hospitals in the 
1980s, when Medicare (i.e., American public health insur-
ance) provided strong incentives to hospitals to shorten 
the length of hospital stay(15). In clinical practice, chronic 
disease management is defined as an organized, proac-
tive, and patient-centered approach involving groups of 
people with a specific disease (or subpopulations with 
specific risk factors). Care is focused and integrated on the 
whole person, considering the spectrum of the disease 
and its complications, and aimed at preventing comorbidi-
ties. Essential components include identifying the popu-
lation as well as implementing clinical practice guidelines 
and other tools for decision making(16). 
Thus, the current study assessed adherence to phar-
macological therapy and identified related variables 
among a group of patients with hypertension enrolled in a 
chronic disease management program. 
mEtHod
This longitudinal and retrospective study used a 
quantitative approach to investigate patients with hyper-
tension who participated in a chronic disease manage-
ment program for 17 months between 2011 and 2012. 
The study was conducted at the Department of Chronic 
Disease Management of a private institution in São Pau-
lo, Brazil, that was contracted by health insurance com-
panies. Nurses performed the program by systematically 
guiding patients with hypertension using telephone con-
tact and home visits. 
After admission to the program, a risk stratification was 
conducted based on the number of comorbidities, hospi-
talizations, and the presence of diseases such as cancer, 
heart failure, urinary incontinence, coronary artery disease, 
osteoporosis, or kidney failure. The predictive score for 
hospitalization ranged from 0 to 100, and higher scores de-
noted greater risk. Thus, Statuses 1 through 5 correspond-
ed to ≥40%, ≥30%, ≥20%, ≥10%, and <10% possibilities of 
hospitalization, respectively. After patient classification, 
the following approach timeline was established: Status 
1 - extreme risk, telephone contact at least every 10 days 
with quarterly home visits; Status 2 - high-risk, telephone 
contact between 10 and 21 days with quarterly home vis-
its; Status 3 - moderate risk, telephone contact between 15 
and 30 days with quarterly home visits; Status 4 - low-risk, 
telephone contact between 30 and 60 days without pre-
scheduled home visits; and Status 5 - self-care, telephone 
contact at least every 90 days without home visits. 
An action plan established by the nurse who made 
first contact with the patient directed the telephone 
guidance. The actions were established in accordance 
with the priorities identified for each patient and re-
corded on an electronic medical record worksheet. 
Actions were scored with stars from one to five; more 
stars denoted higher priorities for the action to be im-
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plemented. In addition to this visual method, the nurse 
was also able to assign a specific date for the action to 
be executed. At the end of each telephone call, the next 
call would be scheduled. In addition, approximately 
100 brochures that described the program’s course-
work were created. Depending on what was worked on 
with the patient, at least one brochure would be sent 
to consolidate the information provided by the nurse 
after each call. The major subjects covered in the bro-
chure centered on the issue of hypertension as a chron-
ic disease; drug and non-drug treatments; risk factors 
including obesity, the excessive intake of salt and fats, 
smoking, physical inactivity, alcohol consumption, and 
stress; and the importance of regular blood pressure 
measurements and receiving regular physical examina-
tions. After the home visits, the nurses updated the pa-
tient data in the electronic medical records. During the 
home visits, assessments of blood pressure, blood glu-
cose, weight, height, and waist circumference were per-
formed; in addition, annotations regarding the results 
from the laboratory tests performed on patients were 
made. The guidelines listed in the action plan were also 
reinforced on these occasions. 
The inclusion criteria for this study were a diagnosis 
of hypertension and classified as Status 2 or 3. The exclu-
sion criteria were the presence of a neurological disease 
or a dependency on others that hindered direct com-
munication. An a priori sample size calculation was not 
conducted because all patients who followed the criteria 
participated in the study (see Figure 1). All participants 
were monitored from January 2011 (the inclusion date in 
the program) to the early second half of 2012. 
The data for this study were collected from the 
notes made on the patients’ electronic medical records. 
Thus, patients reported data concerning blood pressure, 
weight, and height via telephone. Data concerning hab-
its and lifestyles such as smoking, alcohol consumption, 
and physical activity were assessed using dichotomous 
responses (yes and no) to the following questions: Do 
you currently smoke?; Do you drink alcoholic beverag-
es?; and Do you perform regular physical activity? Body 
mass index (BMI; weight [kg]/height2 [m]) was classified 
using the World Health Organization (WHO) categories(17) 
as normal (18.5-24.9), overweight (25-29.9), or obese 
(≥30). Systolic blood pressures less than 140 mmHg and 
diastolic blood pressures less than 90 mmHg were con-
sidered controlled (2). 
To assess pharmacological treatment adherence, the 
Morisky-Green test, which is widely used and validated 
in our setting, was used(18). This instrument consists of 
four dichotomous (yes/no) questions. Treatment adher-
ence was met when all of the responses to the follow-
ing questions were negative: Do you ever forget to take 
your medicine?; Are you careless at times about taking 
your medicine? When you feel better do you sometimes 
stop take the medicine, do you taking it? Sometimes if 
you feel worse when you take the medicine, do you stop 
taking it? 
The results of this study were divided into five periods 
that represent the data analyzed over the correspond-
ing five quarters when patients with hypertension were 
monitored. These data are related to the information ob-
tained from the telephone interviews. The data analysis 
did not distinguish between patients with hypertension 
classified as Status 2 or 3. Statistical analyses were per-
formed at a significance level of p<0.05. The relationship 
between variables was assessed using the chi-square 
test and Fisher’s exact test, and means were compared 
with Student’s t-test. The Research Ethics Committee ap-
proved this study under no. 07792512.3.0000.5392; the 
Research Ethics Committee of the medical institution 
where the data were collected performed approved this 
study under no. 01/2013.
RESUltS
The data from this study indicate that most of the pa-
tients with hypertension who participated in a chronic dis-
ease management program were females (62.5%) in their 
70s (mean=73.4 [10.9 years]); 89% were older than 60 
years. Regarding habits and lifestyles, only 3.5% reported 
smoking and 10.2% reported consuming alcohol at enroll-
ment; however, the presence of inactivity was significant 
(96.8%). With regard to the biometric parameters, BMI was 
within the normal range in approximately one third (30.8%) 
of the patients; the others were overweight or obese, and 
the mean weight was in the overweight range (i.e., 27.7 
[4.9] kg/m2). Slightly over 10% of the patients had grade 
Participants in the chronic
disease management program
Hypertensive patients
5.970
1.365
221 Patients with neurological
diseases
123 – Dependent on others
344 Excluded
1.021
Hypertensive patients
45 – Status 1
369 – Status 4
324 – Status 5
738 Excluded
283
Eligible participants
with hypertension
Figure 1 – Flowchart of the inclusion of patients with hypertension
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II (7.1%) or morbid (2.1%) obesity. Although mean blood 
pressure was within the normal range (128.8 (11.4)/78.9 
(7.8) mmHg), 37.6% of the patients with hypertension 
had blood pressure levels above the recommended limits 
(≥140/90 mmHg); of these, approximately half had isolated 
systolic hypertension (Table 1).
channel blockers (27.6%), and angiotensin-converting 
enzyme inhibitors (17.0%) was also recorded. The use of 
hypolipemic agents was also significant, including statins 
(53.4%). The evaluation of drug treatment adherence us-
ing the Morisky-Green test at admission revealed that 
only 25.1% of patients with hypertension adhered to the 
anti-hypertensive treatment, and 37.6% did not control 
their blood pressure (Table 2). With regard to the num-
ber of anti-hypertensive drugs used, 27.9% reported using 
only one medication, whereas 43.1% used two or three 
medications. Surprisingly, 6% of patients with hyperten-
sion reported not using any anti-hypertensives. 
Table 1 - The biometric parameters and lifestyles of hyperten-
sive patients at admission to the chronic disease management 
program, São Paulo, SP, 2013. 
Variables
Hypertensive patients
N %
Gender
Female 177 62.5
Male 106 37.5
Smoke
Yes 10 3.5
Alcohol consumption
Yes 29 10.2
Sedentary
Yes 274 96.8
BMI (kg/m2)
<18.5 3 1.1
18,5 – 24.9 82 30.8
25 – 29.9 97 36.5
30 – 34.9 59 22.2
35 – 39.9 19 7.1
>40 6 2.3
Mean BMI (sd) in kg/m2 27.7 (4.9)
Age group in years
≤ 40 2 0.7
41 - 50 8 2.8
51 - 60 21 7.4
61 - 70 73 25.8
71 - 80 100 35.3
> 80 79 27.9
Mean age (sd) in years 73.4 (10.9)
Blood pressure systolic/diastolic, mmHg
Optimal (<120/80) 34 13
Normal (<130/85) 104 39.8
Borderline (130-139/85-89) 25 9.6
Stage 1 (140-159/90-99) 24 9.2
Stage 2 (160-179/100-109) 13 5
Stage 3 (> 180/110) 11 4.2
Isolated Systolic >140/<90) 50 19.2
Mean blood pressure (sd), systolic/
diastolic, mmHg 128.8 (11.4)/78.9 (7.8)
Table 2 - Comorbidities, drug treatment, blood pressure con-
trol, and treatment adherence among hypertensive patients at 
admission to a chronic disease management program, São Pau-
lo, SP, 2013.
Variables
Hypertensive patients
N %
Comorbidades
Type 2 diabetes 218 77.0
Heart failure 105 37.1
Dyslipidemia 79 27.9
Chronic renal failure 53 18.7
Coronary artery disease 38 13.4
Stroke 30 10.6
Myocardial infarction 17 6.0
Type 1 diabetes 10 3.5
Medications 
Angiotensin receptor blockers 156 55.1
Statins 151 53.4
Diuretics 149 52.7
Beta-blockers 108 38.2
Hypoglycemic agents 105 37.1
Calcium channel blockers 78 27.6
Angiotensin-converting enzyme inhibitors 48 17.0
Insulins 29 10.3
Antiarrhythmics 22 7.8
Central adrenergic agonists 4 1.4
Adherence to medication  (Morisky-Green test)
Yes 71 25.1
No 212 74.9
Controlled blood pressure 
Yes 163 62.4
No 98 37.6
The drug treatment adherence of hypertensive patients 
(as assessed by the Morisky-Green test) showed a significant 
change across the follow-up periods (p<0.05). An increase 
was observed beginning at period 2 that persisted across pe-
riods 3, 4, and 5. The initial treatment adherence index was 
25.1%, and it increased to 85.5% at the end of the assess-
ment. A significant decrease in blood pressure (p<0.05), both 
systolic and diastolic, was observed between period 1 and 
periods 4 and 5 (Table 3). 
The clinical characterization of patients with hyperten-
sion revealed that type 2 diabetes was the most prevalent 
comorbidity (77%). Approximately 56.5% of patients had 
at least one type of heart disease; dyslipidemia (27.9%) 
and renal failure (18.7%) were less commonly observed. 
With regard to the pharmacological classes of anti-hy-
pertensive medications, 55.1% of patients reported us-
ing angiotensin receptor blockers, and 52.7% reported 
using diuretics. The use of beta-blockers (38.2%), calcium 
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Table 4 - Drug treatment adherence relative to the comorbidities of and the anti-hypertensives used by hypertensive patients en-
rolled in a chronic disease management program, São Paulo, SP, 2013.
Variables s
Drug treatment adherence
Yes No Total
p-valvue
N % N % N %
Anti-hypertensives Drug
Angiotensin receptor blockers
Yes 134 53.0 22 73.3 156 55.1 0.03
No 119 47.0 8 26.7 127 44.9
Diuretics
Yes 133 52.6 16 53.3 149 52.7 0.23
No 47.4 14 46.7 134 47.3
Beta-blockers
Yes 96 37.9 12 40.0 108 38.2 0.83
No 157 62.1 18 60.0 175 61.8
Channel calcium blockers
Yes 70 27.7 8 26.7 78 27.6 0.91
No 183 72.3 22 73.3 205 72.4
Angiotensin-converting enzyme inhibitors
Yes 47 18.6 1 3.3 48 17 0.03
No 206 81.4 29 96.7 235 83
Comorbidades
Type 2 diabetes
Yes 193 76.3 25 83.3 218 77 0.38
No 60 23.7 5 16.7 65 23
Heart disease
Yes 116 45.8 14 46.7 130 45.9 0.54
No 137 54.2 16 53.3 153 54.1
Table 3 - Drug treatment adherence and blood pressure values among hypertensive patients across the five evaluation periods at a 
chronic disease management program, São Paulo, SP, 2013.
Variables
Evaluation periods
1 2 3 4 5
N % N % N % N % N %
Drug treatment adherence
Yes 71 25.1 150 53 184 65 209 73.9 242 85.5
No 212 74.9 133 47 99 35 74 26.1 41 14.5
p-valvue* 0.00 0.00 0.00 0.00
Mean blood pressure (sd) mmHg
Systolic 128.8 (11.4) 128.2 (11.9) 127.8 (11.90) 126.1 (10.9) 125.1 (11.6)
p-value 0.61 0.23 0.02 0
Diastolic 78.9 (7.8) 79.7 (9.4) 78.5 (7.3) 77.3 (7.0) 77.2 (8.0)
 p-value § 0.11 0.95 0.03 0.05
* p-value at period 1 vs. periods 2, 3, 4 and 5 § p-value at period 1 vs. periods 4 and 5
Note: Data analyzed using the chi-square test
Continued...
The drug treatment adherence of hypertensive patients 
(as assessed by the Morisky-Green test) showed a signifi-
cant change across the follow-up periods (p<0.05). An in-
crease was observed beginning at period 2 that persisted 
across periods 3, 4, and 5. The initial treatment adherence 
index was 25.1%, and it increased to 85.5% at the end of 
the assessment. A significant decrease in blood pressure 
(p<0.05), both systolic and diastolic, was observed between 
period 1 and periods 4 and 5 (Table 3).
A significant association was observed between 
drug treatment adherence at period 5 and the use of 
angiotensin-converting enzyme inhibitors; specifically, pa-
tients with hypertension who used this medication were ad-
herent (p<0.05, 18.6% vs. 3.3%). In contrast, those treated 
with angiotensin receptor blockers tended not to adhere to 
treatment (p<0.05, 53.0% vs. 73.3%). No associations were 
observed between the other anti-hypertensive medications 
and treatment adherence. In addition, patients with hyper-
tension and chronic renal failure were more adherent than 
those who did not have this comorbidity (p<0.05, 20.6% vs. 
3.3%). Other comorbidities were not associated with treat-
ment adherence (Table 4). 
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diScUSSion
The major finding of this study is the marked increase 
(p<0.05) in drug treatment adherence, as assessed by 
the Morisky-Green test, throughout the evaluation 
period among patients with hypertension in a chronic 
disease management program. The Morisky-Green test 
is designed to identify and evaluate the problems and 
barriers to appropriate adherence. This test can be used 
initially as a diagnostic tool to assess adherence behav-
iors and the level of compliance with drug treatment. 
An important feature of the Morisky-Green test is its 
ability to identify problems associated with attitudes 
and behaviors as well as the consequent use of appro-
priate measures to address them. The adherence rate 
in the current study increased approximately 60% (i.e., 
from 25.1% at admission to 85.5% during the last evalu-
ation period). This observation was positively reflected 
in the blood pressure measurements, which showed 
evident decreases.
Evaluating adherence to chronic disease treatments, 
such as those for hypertension, is not an easy or simple 
task. Several factors affect the adherence process such 
as gender; age; socioeconomic status; the disease itself, 
including its chronicity, the absence of specific symp-
toms, and the presence of late complications; aspects 
of the treatment such as undesirable medication side 
effects and complex regimens; and institutional aspects 
such as access to health services and the relationship be-
tween the patient with hypertension and the healthcare 
team(12). Although no significant associations were ob-
served between adherence and either gender or treat-
ment, the fact that most of the participants were female 
septuagenarians might have increased their adherence 
levels to the drug treatment. Studies have revealed that 
adherence levels tend to be greater after 60 years of 
age(19,20). Aging and the greater involvement in health-
care issues of patients with hypertension might lead to 
greater treatment adherence and improve disease con-
trol. Women seem to have more accurate perceptions of 
their health conditions and develop deeper relationships 
with healthcare services as a result of their attributes 
and reproductive functions. 
Anti-hypertensive drug characteristics such as un-
desirable side effects, life-long treatments, and regi-
mens involving various medications might also affect 
the adherence process. The current study revealed a 
positive association between medication adherence 
and the use of angiotensin-converting enzyme inhibi-
tors; however, the opposite pattern was observed with 
regard to the use of angiotensin receptor blockers. An-
giotensin II (AT1) receptor blockers (ARB II) antagonize 
the action of AT1 by specifically blocking its receptors. 
These medications are indicated to treat hypertension, 
especially among populations at high cardiovascular 
risk or with comorbidities and promote the reduction 
of cardiovascular morbidity and mortality(21,22). A meta-
analysis found that patients with hypertension who use 
angiotensin-converting enzyme inhibitors were 30% 
less likely to adhere than those who use angiotensin re-
ceptor blockers(23). A likely explanation for this finding 
is the extensive use of angiotensin receptor blockers 
among the patients with hypertension studied (55.1%); 
in fact, it was the most frequently used medication. An-
other explanation is the number of medications used 
by the patients: 66% reported using more than two 
anti-hypertensive drugs, and the number of prescribed 
medications is the most important factor that hinders 
treatment adherence in a complex treatment regimen. 
In addition, the significant presence of comorbidities 
that require treatments with specific medications is 
noteworthy.
Another finding that deserves attention is that pa-
tients with hypertension and chronic renal failure were 
clearly more adherent to the drug treatment. This find-
ing might be explained by the greater severity of their 
conditions, which resulted in more intensive healthcare. 
Hypertension can be controlled with drug and non-drug 
treatments. However, deleterious effects (e.g., the dete-
rioration of renal function) can occur with injury to tar-
get organs when the disease is not properly treated and 
Variables s
Drug treatment adherence
Yes No Total
p-valvue
N % N % N %
Chronic renal failure
Yes 52 20.6 1 3.3 53 18.7 0.02
No 201 79.4 29 96.7 230 81.3
Stroke
Yes 25 9.9 5 16.7 30 10.6 0.34
No 228 90.1 25 83.3 253 89.4
Dyslipidemia
Yes 69 27.3 10 33.3 79 27.9 0.48
No 184 72.7 20 66.7 204 72.1
Note: Data analyzed using Fisher’s exact test
Continuation...
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blood pressure is not decreased to desirable levels(24). A 
more aggressive blood pressure reduction is indicated 
for patients with hypertension and impaired renal func-
tion; the treatment of hypertension should aim for a 
blood pressure of 130/80 mmHg(2). A 15-year follow-up 
cohort study of patients with hypertension showed a de-
creased risk of renal failure with a reduction in systolic 
blood pressure after establishing an anti-hypertensive 
treatment(25). Thus, the relationship between higher 
treatment adherence among patients with chronic renal 
failure can be explained by their need to maintain opti-
mal blood pressure levels to slow the degeneration pro-
duced by this pathology. 
Strikingly, despite the increased treatment adher-
ence observed during the follow-up assessment of pa-
tients with hypertension, blood pressure measurement 
remained controlled in approximately 60% of patients. 
However, this value can be considered reasonable com-
pared with the findings in the literature. In a recent 
systematic review of population-based studies con-
ducted in Brazil, the highest blood pressure control in-
dex (57.6%) was obtained in a multicenter study of 100 
Brazilian municipalities, where the lowest percentage 
(approximately 10%) was observed(26). The VI Brazilian 
Guidelines on Hypertension indicate that the average 
control of hypertension in this country is only 19.2%. 
In general, however, these levels oscillate at approxi-
mately 30%(2). 
The education for individuals with chronic diseases 
such as hypertension is intended to influence their be-
haviors to change their lifestyles and adhere to treat-
ment. The educational objectives are helping them 
to understand, acknowledge, and accept the disease; 
knowing and recognizing risk behaviors; informing them 
about treatment decisions and diagnoses; negotiating 
and complying with treatment proposals; and facing 
problems with treatment maintenance. The challenge of 
hypertensive treatment adherence requires the involve-
ment and participation of the patient and the healthcare 
team, especially the nurses and their staff. To achieve 
and maintain controlled blood pressure levels, constant 
stimuli that might contribute to lifestyle changes and 
medication adjustments are required. Patients with hy-
pertension should be observed at regular intervals to 
control and maintain their blood pressure levels over the 
long term. The primary reason for the inadequate con-
trol of hypertension appears to be patients’ non-compli-
ance with long-term treatments, both through changes 
in lifestyle and adhering to medication regimes. Thus, 
chronic disease management proposals directly affect 
these factors, and studies have recognized the beneficial 
effects of these strategies(27,28). The ease of access to the 
target population via telephone is also important given 
the mobile phone system and technological advances 
in the field. A clinical trial conducted in Brazil compared 
two groups of patients with hypertension and showed 
that those who received telephone calls had lower treat-
ment dropout rates (p<0.05)(14). 
Currently, therapeutic, pharmacological, and non-
pharmacological measures exist to effectively treat 
hypertension. However, unsatisfactory disease con-
trol rates are associated with these measures, leading 
hypertensive patients to have problems arising from 
complications. This lack of control is directly related to 
the lack of treatment adherence. Adherence, in turn, 
is composed of a series of factors that are strongly re-
lated to the risk factors for hypertension itself. In the 
individual risk stratification of patients with hyperten-
sion, the search for variables beyond those specified in 
consensus statements and guidelines are an important 
prerequisite to recognize strategies that facilitate the 
desired treatment adherence, adequately control the 
disease, and prevent treatment attrition. Poor treat-
ment adherence is a problem that must be faced by 
hypertensive individuals, families, communities, insti-
tutions, and healthcare teams. Public healthcare poli-
cies should be directed at all of these parties; however, 
special attention should be provided to patients with 
the uncontrolled hypertension who should be provided 
with special promotion, prevention, and control strate-
gies to minimize or prevent complications. 
Study limitations 
The major limitation of the current study is its design: 
An observational study cannot evaluate the relationship 
between cause and effect. Although changes occurred in 
the variables over time, the absence of a control group 
does not allow these changes to be related to the inter-
vention applied. Another limiting factor was the data 
collection from electronic medical records. Some data, 
such as those from laboratory tests, were absent from 
the records, which hampered the analysis of certain vari-
ables. Many records did not contain sufficient informa-
tion during the analyzed period. However, the lack of 
data cannot be attributed to the absence of notes from 
the nurses or to a lack of knowledge regarding the par-
ticipants’ data.
conclUSion
The chronic disease management strategy, with the 
participation of nurses working to guide patients with 
hypertension via the telephone, might have increased 
adherence to their medication therapy. The adoption of 
strategies aimed at changing the morbidity and mortal-
ity of diseases such as hypertension should be a goal for 
all levels of healthcare. The importance of a nurse for pa-
tients with hypertension is undeniable, especially with re-
gard to treatment adherence, which often requires major 
changes in lifestyle that are revealed over the medium or 
long term. Therefore, maintaining relationships through 
the chronic disease management programs that remain 
incipient in Brazil should be encouraged.
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